Aim: We assessed bleeding pattern, tolerance and patient satisfaction of an oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl estradiol (DRSP/EE) under real-life conditions. Study Design: We performed...Aim: We assessed bleeding pattern, tolerance and patient satisfaction of an oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl estradiol (DRSP/EE) under real-life conditions. Study Design: We performed a multicenter, prospective, 6-cycle, observational study in Canada, Europe and the Middle East. Detailed analyses of the three Middle East countries, Jordan, Lebanon andSyriawere presented here. The efficacy variables included an assessment of bleeding patterns, premenstrual symptoms of water retention and patient satisfaction, as determined by a visual analogue scale. Results: A total of 914 women were enrolled. The percentage of women with intermenstrual bleeding decreased from 37.4%, 48.7% and 32.2% at baseline to 9.7%, 6.1% and 10.9% at the end of cycle6 inJordan, Lebanon and Syria, respectively (creased sharply in all three countries (p Amenorrhea decreased significantly in Lebanon and Syria (p < 0.005). In addition, signs of water retention like abdominal bloating, breast tenderness and swelling of extremities decreased significantly over the course of 6 treatment cycles (p < 0.001). Patient satisfaction increased for all investigated items. Upon completion of the study, 82.7% of women answered “Yes” to continue treatment with this oral contraceptive. Conclusion: The oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl estradiol has beneficial effects on bleeding pattern, symptoms of water retention and patient satisfaction.展开更多
In the period from October 1984 to December 1993, 1657 cases of Norplant implantswere observed, and menstrual records of the first 548 subjects were returned and analyzedfor vaginal bleeding patterns in users of the N...In the period from October 1984 to December 1993, 1657 cases of Norplant implantswere observed, and menstrual records of the first 548 subjects were returned and analyzedfor vaginal bleeding patterns in users of the Norplant implants. Results showed: The average total number Of vaginal bleeding days and the number of spotting days in the firstreference period of 90 days was 33. 0 days and 21. 5 days, respectively; in the 4th reference period (at one year) it was 26. 7 days and 13. 8 days, respectively. The number wasdecreased further in the 20th reference period to 20. 2 days and 9. 5 days. Amenorrhea accounted for 0. 5~ 5. 4% women in different reference periods. Conclusions: Use of theNorplant implants showed the gradual decrease of the average total number of vaginalbleeding days with the passage of time, mainly, the decrease in spotting days. The occur-rence of bleeding days and profuse bleeding days did not show any great change.展开更多
文摘Aim: We assessed bleeding pattern, tolerance and patient satisfaction of an oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl estradiol (DRSP/EE) under real-life conditions. Study Design: We performed a multicenter, prospective, 6-cycle, observational study in Canada, Europe and the Middle East. Detailed analyses of the three Middle East countries, Jordan, Lebanon andSyriawere presented here. The efficacy variables included an assessment of bleeding patterns, premenstrual symptoms of water retention and patient satisfaction, as determined by a visual analogue scale. Results: A total of 914 women were enrolled. The percentage of women with intermenstrual bleeding decreased from 37.4%, 48.7% and 32.2% at baseline to 9.7%, 6.1% and 10.9% at the end of cycle6 inJordan, Lebanon and Syria, respectively (creased sharply in all three countries (p Amenorrhea decreased significantly in Lebanon and Syria (p < 0.005). In addition, signs of water retention like abdominal bloating, breast tenderness and swelling of extremities decreased significantly over the course of 6 treatment cycles (p < 0.001). Patient satisfaction increased for all investigated items. Upon completion of the study, 82.7% of women answered “Yes” to continue treatment with this oral contraceptive. Conclusion: The oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl estradiol has beneficial effects on bleeding pattern, symptoms of water retention and patient satisfaction.
文摘In the period from October 1984 to December 1993, 1657 cases of Norplant implantswere observed, and menstrual records of the first 548 subjects were returned and analyzedfor vaginal bleeding patterns in users of the Norplant implants. Results showed: The average total number Of vaginal bleeding days and the number of spotting days in the firstreference period of 90 days was 33. 0 days and 21. 5 days, respectively; in the 4th reference period (at one year) it was 26. 7 days and 13. 8 days, respectively. The number wasdecreased further in the 20th reference period to 20. 2 days and 9. 5 days. Amenorrhea accounted for 0. 5~ 5. 4% women in different reference periods. Conclusions: Use of theNorplant implants showed the gradual decrease of the average total number of vaginalbleeding days with the passage of time, mainly, the decrease in spotting days. The occur-rence of bleeding days and profuse bleeding days did not show any great change.
